Bioactive peptides may act as agents against type 2 diabetes due to their ability to inhibit the enzymatic activity of dipeptidyl peptidase-IV (DPP-IV), α-amylase, and α-glucosidase [33]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.